1 Cost-effectiveness analysis of social distancing strategies to prevent SARS-CoV2 spread

- 3 Amir Shlomai MD, PhD1, Ari Leshno MD2, Ella H. Sklan PhD3\*+, Moshe Leshno MD, PhD4\*
- 5 1 Department of Medicine D and The Liver Institute, Rabin Medical Center,
- 6 Beilinson Hospital, Petah-Tikva, Israel and The Sackler Faculty of Medicine, Tel Aviv
- 7 University, Tel Aviv, Israel.

2

4

13

20

- 8 2 Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel and The Sackler Faculty
- 9 of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 10 3 Department of Clinical Microbiology and Immunology, The Sackler Faculty of Medicine, Tel
- 11 Aviv University, Tel Aviv, Israel.
- 12 4 The Coller School of Management, Tel Aviv University, Tel Aviv, Israel.
- \* These senior authors contributed equally to this article;
- 15 +Corresponding author:
- 16 Ella H. Sklan sklan@tauex.tau.ac.il
- 17 Mailing Address: Department of Clinical Microbiology and Immunology, Sackler School of
- 18 Medicine, Tel-Aviv University, Ramat Aviv, Tel Aviv, ISRAEL, 69978.
- 19 *Phone:* +972-3-6408197
- 21 Running title: cost-effectiveness of social distancing measures
- 22 Keywords: SARS-CoV-2; Cost-effectiveness; SEIR model.
- 24 Article Summary Line: The Cost-effectiveness of two major strategies to control the spread of
- 25 SARSUE THE president that has not been certified by peer review and should not be used to guide clinical practice.

- 26 Conflict of interests: The authors declare no conflict of interests regarding this work
- 27 Funding: There is no funding to declare regarding this work
- 28 *IRB*: This work has an IRB exempt (approval attached)

While highly effective in preventing SARS-CoV-2 spread, global quarantine comes with an enormous economic price. Few countries have adopted an alternative "testing, tracing, and isolation" approach to selectively isolate people at high exposure risk, thereby minimizing the economic impact. However, the cost-effectiveness of these approaches was never tested. A modified Susceptible, Exposed, Infectious, Recovered (SEIR) model was used to test these strategies and the incremental cost-effectiveness ratio (ICER) was calculated. The expected number of deaths under global quarantine is 322 vs. 464 under focused isolation. However, the ICER in the case of global quarantine will be \$75,110,000 to prevent one case of death. Thus, global quarantine has a moderate advantage in saving lives with tremendous costs that might result in overwhelming economic effects. These findings should be considered by decision-makers, while preparing for a possible "second wave" of the pandemic or as a lesson for future pandemics.

\*\*Text—word count\* (3403)\*

## Introduction:

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Since its identification at the very end of 2019, the novel coronavirus (SARS-CoV-2) has been spreading around the world at an extraordinary rate and has now been officially declared a pandemic (1). Observing the dreadful situation in countries such as Italy and Spain (2) and following social distancing measures, travel bans and isolation of infected patients and their close contacts (3), many countries are now undertaking extreme measures such as global quarantine, in the effort not to overwhelm their health systems. However, only a few countries, such as South Korea, have succeeded in slowing the infection rates without employing economically damaging lockdowns. Instead, South Korea applied early interventions that included identification and isolation of outbreak sources by massive screening of infected patients and aggressive tracing and isolation of their contacts (4). It is not yet clear whether the apparent success of South Korea could be applied to other countries in North America and Europe. It is, however, obvious that extreme non-selective measures are associated with tremendous economic costs and will result in a global financial crisis that will most likely affect public health and other essential aspects of our lives in the coming years. Therefore, as we might face "second waves" of this epidemic and as a lesson for future epidemics, the cost-effectiveness of these two approaches should be compared. In this study, we applied a modified Susceptible, Exposed, Infectious, Recovered (SEIR) model (5), comparing two major strategies: 1. Complete global (non-selective) quarantine of the whole population; 2. Focused isolation and massive screening of individuals at high exposure risk, who, after testing negative, will return to the workforce under social distancing measures together with the rest of the susceptible population. The study aimed to analyze the costeffectiveness of these strategies in reducing the spread of SARS-CoV-2 and preventing death. The model's variables are compatible with currently established parameters in the literature and

- rely on the actual number of infected patients and deaths in Israel, a country with a population of
- approximately 9 million, at the beginning of May 2020.
- 74 *Methods*:
- 75 *Model construction:*
- A simulation model of SARS-CoV-2 transmission was constructed (Fig S4). The model includes
- six compartments (modified SEIR model(5)):
- 78 1. Susceptible (S): Individuals susceptible to SARS-CoV-2 infection.
- 79 2. Exposed (E): Individuals infected with SARS-CoV-2, who can transmit the virus to
- susceptible individuals. These exposed individuals may be tested for SARS-CoV-2 and
- isolated accordingly. We further divided the exposed state into two compartments: exposed
- people who do not develop clinical symptoms (EA) and exposed people who will develop
- 83 clinical symptoms (I).
- 84 3. Exposed asymptomatic (EA): Patients infected with SARS-CoV-2 who do not develop
- clinical symptoms and can transmit the virus to susceptible patients. These patients may be
- tested for SARS-CoV-2 and isolated accordingly.
- 4. Infected (I): Patients with symptoms of the disease will be tested for SARS-CoV-2, using a
- PCR test with close to 100% sensitivity. Patients with confirmed infection will be placed in
- 89 complete isolation to prevent further transmission.
- 90 5. Recovered (R): Patients who were infected with SARS-CoV-2 and recovered (recovery does
- 91 not confer lifelong immunity).
- 92 6. Death (D): Patients who died because of coronavirus disease 2019 (COVID-19)
- 93 complications.
- The mathematical ordinary differential equations (ODE) that illustrate our model are displayed
- 95 in Figure S4.

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

 $\beta$  — transmission rate from carriers (E) to the susceptible population (S). We assume that the transmission rates from the infectious population (I) and from the carrier population (EA) are identical. However, if infectious subjects are isolated, the rate of transmission from the "I" to the "S" population will decrease. If the size of the "I" population decreases by 50% due to isolation, the rate of transmission from "I" to "S" will decrease by 50% ( $\beta 1=\beta x50\%$ ). Similarly, if we isolate the "E" population, the transmission rate from "E" to "S" will decrease accordingly (β2).  $\theta$  – the proportion of exposed individuals that will develop symptoms.  $\sigma$  – transition rate from carrier state (E) to infected state (the time from exposure to symptom onset), assuming that the incubation period has an exponential distribution.  $\delta$  – mortality rate of the infected population.  $\gamma$  – recovery rate of the infected population.  $\alpha$  – transmission rate from the recovered population to the susceptible population. Ro (Reproductive Number) – the expected number of secondary infections from an infected individual. If Ro<1, then the pathogen will be cleared from the population. Otherwise, the pathogen will be able to infect the whole susceptible population. Note that  $Ro = \frac{\beta}{v}$ . We estimated the number of deaths and the total cost of each strategy (described below) and calculated the cost per avoided death (denoted by incremental cost-effectiveness ratio (ICER). The costs were based on the gross domestic product (GDP) per capita in Israel (\$40,270) or GDP per capita per day, namely \$130. In the model, we estimated that the cost of isolating one person per day is \$70. The time horizon in the model was 200 days. Strategies: We define three levels of actions: **Social distancing** – maintaining a 2-meter distance between people outside a household at all times, wearing face masks in all public places, avoiding large group gatherings.

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

**Quarantine** – separating people and limiting movement of people by confining them to their homes to prevent exposure and infection. There is no limit on interactions between people living in the same house hold. **Isolation** – complete isolation of infected people or individuals at high exposure risk. This is typically done in a dedicated facility. Home isolation can be achieved by preventing interaction with family members and avoiding sharing of household items. In this study we compare the cost-effectiveness of two strategies (Table S2): Strategy 1: A global quarantine of the susceptible population. Individuals in exceptional circumstances who are not quarantined will be required to maintain social distancing. All known exposed individuals will be under complete isolation. Strategy 2: The susceptible population will be required to maintain social distancing. All known exposed individuals will be under isolation. Individuals who are at high exposure risk due to possible contacts with infected or carrier subjects will be located using detailed epidemiological tracing and/or using mobile phone and satellite technology. These people will be subjected to a 14-day isolation period during which they will be repeatedly tested every three days for the presence of SARS-CoV-2 using PCR. Under this strategy, only the high exposure risk group will be quarantined, while most of the susceptible population will go back to the workforce. In addition, extensive PCR testing will identify carriers and infected individuals within the population and will prevent unnecessary isolation of non-infected individuals. Subjects with two sequential negative PCR results will be removed back into the workforce. We estimated that the length of isolation in the high-risk population will decrease from two weeks to an average of seven days, which is within the range of the average incubation period (6-8). In addition to the two main strategies mentioned above, we estimated the number of deaths and the size of the infectious population, in another hypothetical strategy of no intervention at all.

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

The list of parameters in the model as well as the low and high values that were used for sensitivity analysis are presented in Table 1. Parameter estimation and calibration: The following parameter estimates were used to construct the model (Table 1): Exposed (Carriers E0) were defined as the number of infected individuals who are currently undocumented. For our basic model we estimated 10,000 undocumented carriers. In a screening conducted in Iceland (9), 0.6-0.8% were carriers and 46-59% had symptoms, which yields about 20,000 undocumented carriers. However, after calibration of the parameters, the estimate of 10,000 undocumented carriers had a better fit to the number of deaths in Israel during March 27, 2020 until May 3, 2020 (Fig S5). The initial number of infected individuals (I0) was determined according to the Israeli Ministry of Health publications on March 27, 2020. The number of susceptible individuals was defined as a rounded approximation of the population in Israel (9 million) after subtracting the infected and undocumented carriers. Complete isolation refers to infected individuals who are hospitalized (including individuals in intensive care units) or isolated in a dedicated facility. The isolation costs are calculated using an estimation of the price of lost workdays and hospitalization. Quarantine refers to home confinement and thus the estimated costs include only the price of lost workdays. To calculate the recovery rate  $(\gamma)$ , an estimation of 26 days with a range of 21 to 32 days for the time from symptom onset to recovery was taken, compatible with several recent studies (8, 10-12). The average incubation period ( $\sigma$ ) was estimated to be approximately 5.1 (6-8). We used R0=2.6 (range 2.0-7.2) (13), assuming that the recovery time is 26 days. Thus the transmission rate from infected (carrier) patients to the susceptible population ( $\beta$ ) was 0.1 (range 0.07 to 0.3) (13). As all subjects coming to Israel from abroad are isolated, in the model we did not include imported cases. Case fatality rates vary between different countries, ranging from

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

7.2% in Italy to 0.2% in Germany (14). Thus, for the rate of death ( $\delta$ ) in our basic model we considered a moderate estimate of 2.6% or 0.001 per day over 26 days of infection. RR1-3 represents the probability of the reduction in contacts due to the actions taken. The estimation of these parameters was based on the calibration analysis (Fig. S5). The assumptions used for the two strategies are described in Table S3. In strategy 1, r1 HR c represents the proportion of the population under isolation due to a high risk of contact with SARS-CoV-2 patients (0.7%). Under strategy 1, we estimated the proportion of the susceptible population under quarantine (r\_S) to be 80%, while the proportion of the carrier (r1\_E) population that is under isolation was estimated at 30%. By contrast, under strategy 2 (r2\_HR\_c), the proportion of the population under isolation will be lower (0.3%) due to repeated testing. Under strategy 2, the number of susceptible individuals under quarantine (r2\_S) will be 0, while the proportion of carriers (r1\_E) that are under isolation will remain 30%. The time horizon was 200 days and therefore the discount rate was 0. In addition, favoring strategy 1, we assumed that the cost of isolation is only for 14 days. The analysis was performed using MATLAB. Sensitivity analysis: We used one-way sensitivity analysis of all the parameters in the model (see Tables 1+S3 for the range used for the sensitivity analysis). We constructed the Tornado diagram for the ICER and the number of deaths in each strategy. Monte Carlo simulation: We performed a Monte Carlo simulation to assess the effects of ranging base case variables on model outcomes with 1000 draws from probability distributions of model parameters.

Results:

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

212

213

214

215

216

217

We first tested our model with strategy 1: Global quarantine of the susceptible population, complete isolation of all infected individuals and two weeks of isolation for the high exposure risk group. Applying this strategy will yield a peak of 7,256 infected individuals followed by a rapid decline (Fig. 1, right upper panel) with a total of 15,964 infected individuals over the 200day period. Under this strategy, the number of expected deaths is 322 (Fig. 1, right lower panel). This number will be reached after ~100 days. In the second strategy, infected individuals will remain under complete isolation. However, instead of global quarantine, only high exposure risk individuals will be isolated. These individuals will be tested every four days for SARS-CoV-2 by PCR. Individuals testing negative and the rest of the susceptible population will return to the workforce under social distancing rules. Under these conditions, the maximum number of infected individuals will slightly increase to 8,110, with a total of 23,774 infected individuals over the 200 days period (Fig. 2, right upper panel). The total number of deaths will increase to 464 (Fig. 2, right lower panel). Table S1 summarizes the costs and number of deaths under each strategy. Factoring the cost of workday loss, complete isolation (in a dedicated facility or under hospitalization) and the PCR tests enabled us to calculate the following ICER value:

211 ICER = 
$$\frac{1.0694e+10-8.8015e+07}{464-322} = \frac{1.0606e+10}{142} = 75,110,000$$

Thus, under these conditions, the cost of preventing one death is \$75,110,000.

The results of a one-way sensitivity analysis for both strategies are displayed in Fig 3. The two variables with the strongest influence on ICER were the virus transmission rate ( $\beta$ ) and the daily mortality rate ( $\delta$ ) (Fig 3). A one-way sensitivity analysis showing the effect of these parameters on ICER is displayed in Figure S1.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

An additional sensitivity analysis was performed for the number of expected deaths under both strategies. As shown in Figure S2, the initial carrier population figure, the daily mortality rate  $(\delta)$ and the virus transmission rate  $(\beta)$  were the parameters with the greatest effect on the death rate. A probabilistic simulation analysis (Monte Carlo simulation) of the expected death rate for each strategy and of the expected ICER are displayed in Fig 4 and Fig 5, respectively. The median difference between strategy 1 and 2 in the number of deaths is 93 (95% CI 16-357) and the median ICER is \$ 70.7 million (95% CI 4.4-408.1) per one avoided death. Finally, we tested our model under a situation of no intervention. Starting from a baseline of 10,000 carriers and 3,000 infected individuals, the maximal number of infected individuals is 1.37 million, (Fig. S3, right upper panel). This number will be reached after 200 days. Under these conditions, the expected number of deaths is 123,420 (Fig. S3, right lower panel). Discussion: The SARS-CoV-2 pandemic has serious global consequences and a substantial death rate, affecting 187 countries around the world. So far, this epidemic has affected over 3.2 million people and claimed the lives of more than 233,000 individuals (15, 16). The first priority in most countries is to enable the local health systems to handle the growing number of patients needing hospitalization and intensive care by "flattening the infection curve". In countries that were late in taking drastic steps, the rapid spread of the disease has been accompanied by a high death toll, and an extraordinary sustained burden on the public health system that necessitated controlled distribution and use of scarce medical resources (17). In China, where the pandemic first emerged, drastic measures of global quarantine have successfully controlled virus spread and are now enabling a gradual release of the quarantined population (18). However, adopting these extreme measures carries unprecedented social and economic costs that might, both directly and indirectly, affect the health system and many other aspects of our life in the years to come. While "first wave" of this pandemic is slowly waning in most countries, there is an urgent need

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

to examine the strategies undertaken in terms of cost-effectiveness as a preparation for possible future "waves" of the SARS-CoV-2 pandemic, or as a lesson towards future pandemics. In this study, we applied cost-effectiveness analysis tools to distinguish between two different strategies aimed to slow down the spread of the virus. We show that a global quarantine of the whole population (strategy 1) will result in a total of ~15,964 infected people and around 322 deaths over a period of 200 days. An alternative "testing, tracing, and isolation" approach (strategy 2) in which only high exposure risk individuals are isolated and repeatedly tested will result in a total of 23,774 infected individuals and 464 deaths. Overall, strategy 1 is expected to save ~142 more lives, but with a cost of \$75,110,000 to prevent one case of death, compared to the more focused approach. Usually, ICER in cost-effectiveness analyses relates to cost per quality-adjusted life year (QALY). In our study, ICER was calculated as the cost per one avoided death. We suggest an easy transformation of the ICER in this study to conventional ICER in cost-effectiveness analyses. Assuming that one case of death is equivalent to a loss of 10 QALYs, the ICER would be \$75,110,000 divided by 10, resulting in \$7.5 million per QALY. This number is still very much higher than the \$150,000 per QALY, recommended by Neumann et al. as the threshold of willingness to pay (19). Another parameter, used to assess the cost of death in other fields, is a statistical measure of the willingness to pay for small reductions in mortality risks, known as the value of a statistical life (VSL), estimated to be ~\$ 10,000,000 (20). Similarly, this value is much lower than our calculated ICER. A key component of the "testing, tracing, and isolation" strategy is massive and repeated testing of the population at high exposure risk. We assumed that this should require four PCR tests for each high-risk individual during the 14 days of isolation, meaning ~10,000-15,000 tests daily for a population of 9 million. This number translates to ~1700 tests per million people. For comparison, South Korea performs four times more tests daily, indicating that this approach is feasible (14). Of note, serological tests, when available, might also be used as a part of this

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

strategy. These tests would most likely improve its efficiency since they seem to be able to detect infection from a few days after symptom onset up to several months or more, and thus fewer tests would be needed per high-risk individual (11). One of the major concerns during a pandemic is that the number of patients needing intensive care and mechanical ventilation will overwhelm the local health care system. According to our model, a no-intervention approach will result in an unacceptable number of infected individuals (1.37 million) and an extremely high death rate (~123,420), and therefore is not realistic. In contrast, the difference in the peak number of infected patients between the two main strategies tested is ~854 patients, in favor of strategy 1. Assuming that 10% of patients are at risk of developing a severe form of the disease, this translates into an additional 85 potential hospitalizations and mechanical ventilations at the peak, an acceptable extra burden. As with similar models, the validity of this model is based on the correct assumption of the various parameters. Since SARS-CoV-2 is a new virus and the exact infection rates in the population are still unknown, these parameters are subject to variations and may change over time. To validate our model, we calibrated it by comparing the rate of deaths according to our model assumptions with the real-time published number of this parameter in Israel (Fig. S5). The graphs obtained were strikingly similar, further confirming our model. One major limitation of compartment models is that they assume a homogeneous population, which is not the case in many countries. In Israel, for example, the reproductive number (R0) is most probably higher among some religious groups. This might alter the infection dynamics and affect the outcome of the model. Our sensitivity analysis indicates that  $\beta$  (the transmission rate) is the parameter with the most influence on ICER. β relies on R0, which might change, and on the recovery time, which will most likely remain the same. However, since a similar R0 is used for modeling both strategies, we believe that the difference in the number of deaths and ICER will remain similar.

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

Obviously, strategy 2 of "trace, isolate, test and treat", largely representing the steps successfully undertaken by South Korea to handle the situation, demands two major critical components: 1. Intensive epidemiological investigations of infected patients combined with surveillance to trace possible interactions. 2. Availability of enough testing kits and facilities to enable a large number of daily PCR tests to isolate subjects at high exposure risk. Obviously, the intensive epidemiological investigations, necessary to define people at high exposure risk who must be isolated and repeatedly tested, imply massive use of mobile phone and satellite technology, thereby violating citizens' privacy rights. Therefore, decision-makers must carefully weigh their options in the knowledge that avoiding those extreme steps and choosing global quarantine strategies comes with a very high economic price. In summary, in this cost-effectiveness analysis, we show that a strategy of global quarantine over time is moderately superior to a strategy of focused isolation and repeated testing in terms of reducing death rates, but involves extremely high economic costs to prevent one case of death. These economic costs might add to the future death toll resulting from a possible economic crisis, and thus these options should be carefully considered and balanced. Furthermore, our proposed "trace, isolate, test and treat" strategy is highly relevant as an exit strategy in countries relaxing global isolation or for coping with future "waves', thereby keeping infections levels controlled while returning most of the population to the workforce. Acknowledgements EHS is grateful to the Milner foundation for its support. We thank Gerda Kessler for her assistance in editing this manuscript.

## **References:**

- 319 1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-
- 320 19: towards controlling of a pandemic. The Lancet. 2020 2020/03/17/.
- 321 2. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying
- in Relation to COVID-19 in Italy. JAMA. 2020.
- 323 3. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against
- 324 COVID-19. The Lancet Infectious Diseases. 2020 2020/03/23/.
- 325 4. Cohen J, Kupferschmidt K. Countries test tactics in 'war' against COVID-19. Science.
- 326 2020;367(6484):1287.
- 5. Li MY, Graef JR, Wang L, Karsai J. Global dynamics of a SEIR model with varying total
- 328 population size. Math Biosci. 1999 Sep;160(2):191-213.
- 329 6. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of
- Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020.
- 7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation
- Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed
- Cases: Estimation and Application. Ann Intern Med. 2020 Mar 10.
- 8. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-
- CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature
- 336 Medicine. 2020 2020/03/13.
- 9. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al.
- Spread of SARS-CoV-2 in the Icelandic Population. New England Journal of Medicine.
- 339 2020.
- 340 10. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and Transmission of
- COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts.
- 342 medRxiv. 2020:2020.03.03.20028423.

- 343 11. Amanat F, Nguyen T, Chromikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A
- serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv.
- 345 2020:2020.03.17.20037713.
- 346 12. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in
- 347 Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine.
- 348 2020 2020/03/19;382(12):1177-9.
- 13. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients
- Recovered From COVID-19. Jama. 2020 Feb 27.
- 351 14. Roser M, Ritchie H, Ortiz-Ospina E. Coronavirus Disease (COVID-19) Published online
- at OurWorldInData.org.; 2020.
- 353 15. Worldometers.info. 2020 [cited; Available from: https://www.worldometers.info/
- 354 16. WHO. Coronavirus disease (COVID-19) outbreak. [cited; Available from:
- 355 https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- 356 17. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation
- of Scarce Medical Resources in the Time of Covid-19. N Engl J Med. 2020 Mar 23.
- 358 18. Salzberger B, Gluck T, Ehrenstein B. Successful containment of COVID-19: the WHO-
- Report on the COVID-19 outbreak in China. Infection. 2020 Apr;48(2):151-3.
- 360 19. Neumann PJ, Cohen JT, Weinstein MC. Updating Cost-Effectiveness The Curious
- Resilience of the \$50,000-per-QALY Threshold. New England Journal of Medicine. 2014
- 362 2014/08/28;371(9):796-7.
- 363 20. Kip VW. THE VALUE OF LIFE. Harvard John M Olin Discussion Paper Series
- 364 2005;517.

## 367 Table 1. General assumptions including the range for sensitivity analysis.

	Base	Low	High	comments
E0	10,000	5000	30,000	initial number of carriers
10	3,000	2,000	4,000	initial number of infected individuals
R0	80	0	100	initial number of recovered individuals
D0	12	0	10	initial number of deaths
Cost of global isolation (including hospitalization and ICU, \$)	250	150	350	
Cost of relaxed isolation or quarantine (\$)	70	50	120	
Cost of PCR test (\$)	50	20	75	
$R_0$	2.6	2	7.8	
γ (gamma)	0.038	0.031	0.048	1/time to recovery (21 to 32 days)
β (beta)	0.1	0.07	0.3	Calculated $R_0 \times \gamma$
$\sigma$ (sigma)	0.2	0.08	0.2500	1/incubation time (4 to 12 days)
δ (delta)	0.001	0.0005	0.002	Rate of deaths per day
θ (Theta)	0.7	0.5	1	Proportion of exposed individuals that developed symptoms
RR1	0.35	0.25	0.45	Reduction in probability of contacts due to social distancing
RR2	0.85	0.8	0.9	Reduction in probability of contacts due to quarantine
RR3	0.90	0.85	0.95	Reduction in probability of contacts due to isolation

## Figure legends:

368

369

374

375

- Figure 1: Infection dynamics under global quarantine (strategy 1).
- 371 The graphs display the dynamics within the six compartments over time. Susceptible (S, blue);
- 372 Infected (I, red); Carrier (Yellow, E); Carrier asymptomatic (Yellow, EA); Recovered (R,
- 373 Green), Dead (D, Black).
  - Figure 2: Infection dynamics during isolation of high-risk individuals and extensive testing
- 376 (strategy 2). Graphs are labeled as described under Fig. 1.
- 378 Figure 3: Sensitivity analysis (Tornado diagram) of the incremental cost-effectiveness ratio
- 379 (ICER) between the two strategies. Red bars indicate that the value was produced by the

Lower Bound (Low), and dark blue bars indicate that the value was produced by the Upper Bound (High).

Figure 4: Probabilistic sensitivity analysis for the number of deaths in each strategy. A Monte Carlo simulation was used to assess the probability distribution of the expected number of deaths according to each strategy.

Figure 5: Probabilistic sensitivity analysis for the ICER. A Monte Carlo simulation was used to assess the probability distribution of the ICER (expressed in millions of \$US). The graph was truncated at \$500 million.




Fig 1




Fig 2




Fig 3




Fig 4




Fig 5